Intel stock extends gains after report of possible U.S. government stake
Investing.com - Cantor Fitzgerald initiated coverage on BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) with an Overweight rating on Wednesday. According to InvestingPro data, the company is currently trading at a high earnings multiple but has maintained profitability over the last twelve months.
The research firm highlighted BBOT’s development of potentially first- and best-in-class drugs targeting the RAS pathway, including ON/OFF inhibitors of KRAS and a novel inhibitor of PI3Kα. These pathways represent two of the most commonly mutated pathways in cancer.
BBOT currently has three Phase 1 candidates in its pipeline that could potentially serve up to 250,000 U.S. patients with breast, lung, colorectal, and pancreatic cancers, according to Cantor Fitzgerald’s analysis.
The company, a spin-off from BridgeBio (NASDAQ:BBIO), was incubated within BridgeBio for approximately four years while developing its oncology programs. BBOT was spun out in May 2024 and became publicly listed earlier this month through a SPAC merger with a concurrent private placement.
Cantor Fitzgerald noted that BBOT is well-funded with approximately $490 million in cash, which is expected to fund operations into the second half of 2027.
In other recent news, Helix Acquisition Corp. II has announced a significant development regarding its proposed merger with BridgeBio Oncology Therapeutics. Shareholders of Helix are set to vote on this business combination at an extraordinary general meeting scheduled for August 4, 2025. The U.S. Securities and Exchange Commission has given the green light by declaring effective the registration statement on Form S-4 related to this merger. Proxy materials have been dispatched to Helix shareholders who were recorded as of June 30, 2025. This merger is a noteworthy event for both companies involved and is closely watched by investors. The outcome of the shareholder vote will determine the future course of this proposed business combination.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.